spinal orthopedic News
-
FDA clears nView medical’s first imaging system - nView s1
nView medical Inc. (nView) today announced the U.S. Food and Drug Administration (FDA) clearance of nView s1, the company’s first imaging system, bringing breakthrough imaging technology to surgery. nView’s mission is to make surgery safer, faster, and consistently accurate by creating instant 3D information throughout the surgical procedure. nView s1 integrates the latest ...
-
LifeLink Tissue Bank Announces Partnership with NuTech Spine
LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, announced a new partnership with NuTech Spine and Biologics, in which NuTech will distribute LifeLink allografts to surgeons nationwide for patients in need of sports, orthopedic and spine transplants. Additionally, LifeLink will process custom spine allografts for distribution. Jean Davis, President and ...
-
Top 5 Mistakes Medical Device Inventors Make When They Have A New Idea
The hardest part of developing a new idea is getting started. But getting started without considering this list could cause major project setbacks. Contact me to discuss how I can help navigate the complicated product development cycle and bring your new idea to life. List Below: Hiring an engineer or firm without medical device experience. The nuances of medical devices and specific surgical ...
-
Isto Biologics Launches Influx™ Fibrant, a New Line of Advanced Allograft
Isto Biologics, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies, announced today the launch of Influx™ Fibrant, an unprecedented line of functional constructs derived from 100% cortical allograft. The cutting-edge line consisting of five new products includes Fibrant Anchor, Boat, Bullet, Pak and Wrap. The Fibrant launch features the patented ...
-
Procyrion Names AV Edidin, Ph.D., as Senior Vice President of Development and Manufacturing
Procyrion, Inc., a clinical-stage medical device company developing the Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome), announced the appointment of Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing. In this role, Edidin will lead and oversee product ...
-
How to License or Sell Your Medical Device Intellectual Property
Part I – Presenting Your Idea Anywhere during the product development cycle, it may make sense to discuss your medical device with potential acquirers. Licensing implies that you will still control the company that the technology was developed under and ONLY the intellectual property is transferred to the acquirer. A license can be exclusive (1 company) or non-exclusive (you can license ...
-
Silver Bullet Therapeutics Secures CE Mark Approval for Revolutionary New Antimicrobial Bone Screw System
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that it has received recommendation for CE Mark approval for the commercial sale of its antimicrobial OrthoFuzIon™ Bone Screw System in the European Union for orthopedic reduction and internal fixation procedures anywhere in the body. Over the next few months, Silver Bullet will be finalizing launch ...
-
Transparency notification received from Nyenburgh Holding NV
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 16 March 2022 indicating that the shareholdings held by Nyenburgh Holding NV have crossed below the minimum threshold of 5%. The notification dated 16 March 2022 contains the ...
-
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 ...
-
Bone Therapeutics announces closing of private placement
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the closing of the private placement announced on 3 December 2021, with existing and new institutional investors having purchased 4,832,352 new shares at an issue price of EUR 0.68 per share resulting in gross proceeds of approximately ...
-
Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, today announces that it has signed the definitive subscription agreement for a maximum EUR 5 million convertible bonds (CBs) facility arranged by ABO Securities, through its affiliated entity Global Tech Opportunities 15. The proceeds of the financing will contribute to ...
-
Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you